Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine

Shohei Yamamoto1, Ami Fukunaga1, Akihito Tanaka2

  • 1Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.

Vaccine
|February 20, 2022
PubMed